

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Hutchison Whampoa Limited

*(incorporated in Hong Kong with limited liability)*  
**(Stock Code: 13)**

## OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.5% owned subsidiary of Hutchison Whampoa Limited.

As at the date of this announcement, the Directors of the Company are:

**Executive Directors:**

Mr LI Ka-shing (*Chairman*)  
Mr LI Tzar Kuoi, Victor (*Deputy Chairman*)  
Mr FOK Kin-ning, Canning  
Mrs CHOW WOO Mo Fong, Susan  
Mr Frank John SIXT  
Mr LAI Kai Ming, Dominic  
Mr KAM Hing Lam

**Non-executive Directors:**

Mr George Colin MAGNUS  
Mr William SHURNIAK

**Independent Non-executive Directors:**

The Hon Sir Michael David KADOORIE  
Mr Holger KLUGE  
Mrs Margaret LEUNG KO May Yee  
Mr William Elkin MOCATTA  
*(Alternate to The Hon Sir Michael  
David Kadoorie)*  
Mr WONG Chung Hin

Hong Kong, 30 April 2010



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Hutchison MediPharma Limited Receives SFDA IND Approval and Begins Phase I  
Clinical Trial of Sulfatinib for the Treatment of Cancer**

**London: Friday, 30 April 2010:** Hutchison MediPharma Limited (“Hutchison MediPharma”), the wholly-owned drug R&D subsidiary of Chi-Med, today announces that it has initiated the first-in-human Phase I clinical trial of its anti-cancer drug candidate, Sulfatinib, after it received approval from the State Food and Drug Administration (“SFDA”) in China. The investigational new drug application (“IND”) was reviewed through SFDA’s Green Channel expedited application process. The first patients were dosed on 28 April 2010.

Sulfatinib (HMPL-012) is a novel small molecule that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factors (VEGFs) and fibroblast growth factor (FGF) receptors. Pre-clinical data shows that this compound is a potent suppressor of angiogenesis, an established approach in anti-cancer treatment. It also indicated that it is generally well tolerated in animals. Sulfatinib was discovered and developed internally by Hutchison MediPharma.

The Phase I clinical study is being conducted in China. The trial is an open-label, dose-escalation study. The primary objective of the trial is to estimate the maximum tolerated dose (MTD) and assess the safety and tolerability in patients with advanced solid tumours. The secondary objectives include the assessment of single and multiple dose pharmacokinetics and the evaluation of Sulfatinib’s antitumor activity.

Dr. Samantha Du, Chief Scientific Officer of Chi-Med and Chief Executive Officer of Hutchison MediPharma, said: “This clinical trial approval and its initiation mark a major achievement for the oncology R&D organisation at Hutchison MediPharma. Sulfatinib is a highly potent and selective VEGF signalling inhibitor, and we are very pleased that we have advanced this anti-cancer agent into clinical development. There is a clear medical need for more effective and safe anti-angiogenic treatments for cancer.”

**Ends**

**Enquiries**

**Chi-Med**  
Christian Hogg, CEO

Telephone: +852 2121 8200

**Citigate Dewe Rogerson**  
Anthony Carlisle  
David Dible

Telephone: +44 (0) 20 7638 9571  
Mobile: +44 (0) 7973 611 888  
Mobile: +44 (0) 7967 566 919

**Lazard & Co., Limited**  
Paul Gismondi  
Nick Fowler

Telephone: +44(0) 20 7187 2000

## **Notes to Editors**

### **About the Vascular Endothelial Growth Factor in Cancer Tumours**

Angiogenesis, the process of developing new blood vessels, is critical for tumour cell growth, survival, invasion and metastasis. The vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) play a pivotal role in tumour-related angiogenesis, and the VEGF/VEGFR pathway is an important target for anti-angiogenic drug development and tumour therapy. Inhibition of VEGF signalling in tumour vasculature therefore represents an exciting therapeutic strategy, with the potential to arrest the development of new blood vessels essential for tumour growth and metastasis. Several anti-VEGF agents have shown efficacy in a range of tumour types.

Sulfatinib is a potent, selective, small molecule tyrosine kinase inhibitor of VEGFs. In vivo, Sulfatinib inhibited the growth of multiple human tumors xenografts in mice.

### **About Hutchison MediPharma**

Hutchison MediPharma is Chi-Med's wholly-owned drug R&D subsidiary and has a team of well over 200 scientists and staff focusing on discovery and development of botanical drugs, semi-synthetic natural product drugs, and synthetic single chemical entity drugs. Hutchison MediPharma has a pipeline of single new chemical entity projects in both the auto-immune/inflammatory disease and oncology therapeutic areas.

### **About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.